Nestlé Sells Alcon Stake to Novartis

On 04/01/2010, Swiss pharmaceutical company Novartis officially exercised its call option to purchase Nestlé’s remaining 52% majority stake in eye care company Alcon Inc. for approximately US$28.1 billion. The transaction price was set at US$180 per share and completed the second stage of a multi-year acquisition agreement originally established between Nestlé and Novartis in April 2008. The deal finalized Novartis’ full takeover of Alcon, one of the world’s leading ophthalmology and eye care businesses at the time. Alcon specialized in surgical equipment, vision care products, contact lens solutions, and pharmaceuticals related to eye health. The company had built a strong global position in ophthalmic surgery and consumer eye care products before becoming fully integrated into Novartis. The original agreement signed in 2008 structured the acquisition in two stages. In the first phase, Novartis acquired approximately 25% of Alcon from Nestlé for about US$10.4 billion. The agreement also granted Novartis the option to purchase Nestlé’s remaining controlling stake at a later date. By exercising the option in January 2010, Novartis completed the acquisition process and gained majority control of Alcon. Nestlé had originally acquired its stake in Alcon in 1977 and had held the company for more than three decades. During Nestlé’s ownership period, Alcon expanded into one of the largest eye care businesses globally. The sale generated substantial proceeds for Nestlé and formed part of the company’s broader strategy to concentrate more heavily on nutrition, health science, and core food and beverage operations. The transaction represented one of the largest healthcare acquisitions involving Swiss multinational corporations during that period. Following the acquisition, Novartis integrated Alcon into its pharmaceutical and healthcare operations as part of an effort to strengthen its position in eye care and medical technology markets. Financial analysts closely followed the transaction because of its size and its impact on both companies’ long-term strategic direction. For Novartis, the acquisition significantly expanded its healthcare portfolio beyond pharmaceuticals. For Nestlé, the sale provided major capital resources that were later connected to investments in nutrition science, medical nutrition, and health-focused business expansion initiatives. Why This Moment Matters : The completion of the Alcon transaction marked the end of Nestlé’s long-standing ownership of one of the world’s largest eye care companies and highlighted the increasing specialization of multinational corporations during the late 2000s. The sale also helped finance Nestlé’s strategic shift toward nutrition and health science businesses in the following decade.